[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mesothelial-neoplasm:msln-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mesothelial Neoplasm","MSLN Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06885697","Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma",[12],"Phase 1","RECRUITING","2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.985101Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",[20],"Phase 1\u002FPhase 2","2026-08-26T02:19:12.219640Z","2026-05-05T02:43:26.963212Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05568680","SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:35:31.692599Z"]